LATEST DISCOUNTS & SALES: PROMOTIONS

Close Notification

Your cart does not contain any items

Alzheimer's Disease

Targets for New Clinical Diagnostic and Therapeutic Strategies

Renee D. Wegrzyn Alan S. Rudolph (PhD, MBA, Center for Neuroengineering, Duke University, Durham, North Carolina, USA)

$315

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
CRC Press Inc
26 April 2012
This collection of articles written by international Alzheimer's experts is intended to provide a detailed synopsis of the current state-of-the-art of Alzheimer's Disease across many disciplines. A discussion of current biophysical models and hypotheses regarding the pathology of AD serves as a foundation for a review of research models of AD and recent advances in the fields of in vivo and in vitro AD diagnostics. Experts weigh in on how research advances and accurate diagnostics pave the way for a robust pipeline of therapeutics to combat not only Alzheimer's Disease, but other neurodegenerative diseases via a myriad of different approaches.

Edited by:   , , , , , , ,
Imprint:   CRC Press Inc
Country of Publication:   United States
Volume:   50
Dimensions:   Height: 234mm,  Width: 156mm,  Spine: 23mm
Weight:   566g
ISBN:   9781439827086
ISBN 10:   1439827087
Series:   Frontiers in Neuroscience
Pages:   298
Publication Date:  
Audience:   College/higher education ,  General/trade ,  Primary ,  ELT Advanced
Format:   Hardback
Publisher's Status:   Active
The Amyloid β-Protein and Alzheimer’s Disease. Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer’s Disease. Imaging Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer’s Disease. The Current Status of Alzheimer’s Disease Treatment: Why We Need Better Therapies and How We Will Develop Them. New Small Molecule Drug Discovery for Alzheimer’s Disease. Alzheimer’s Disease: Clinical Aspects. Pathogenic Protein Strains as Diagnostic and Therapeutic Targets in Alzheimer’s Disease. Traumatic Brain Injury in the Development of Alzheimer’s Disease: Risk Factors, Diagnosis, and Treatment Strategies.

Renee D. Wegrzyn obtained her PhD in applied biology from the Georgia Institute of Technology where she studied the propagation of prion proteins in model systems. Dr. Wegrzyn was awarded an Alexander von Humboldt Research Fellowship for her postdoctoral studies to investigate de novo protein folding at the ribosome. She applied her expertise in protein folding to the challenge of developing in vitro diagnostics for neurodegenerative diseases—including Alzheimer’s and prion diseases—as a group leader at Adlyfe, Inc. She is currently a scientific and technical consultant for the Department of Defense. Alan S. Rudolph is currently a member of the senior executive service and director of Biological and Chemical Technologies for the Defense Threat Reduction Agency. He was previously chief executive officer at Adlyfe Inc., an amyloid diagnostic and biomarker company, chief of Biological Sciences at the Defense Advanced Research Projects Agency, and director of Research at the Naval Research Laboratory. He has over 90 publications in diverse areas in biophysics of cryobiology and anhydrobiosis, lipid and protein self-assembly, liposome science and technology, and tissue and cellular engineering. He has a PhD in zoology from the University of California at Davis and an MBA from the George Washington University.

See Also